Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Paras Healthcare raises Rs 275 crore from Creador

      Paras Healthcare raises Rs 275 crore from Creador

      Ruby Khatun Khatun17 July 2017 3:00 PM IST
      New Delhi: Paras Healthcare said it has raised Rs 275 crore from an affiliate of Creador LLP to fund the company's growth and expansion plans.Paras...
      Novartis stocks drug cabinet with Big-3 arthritis blockbusters

      Novartis stocks drug cabinet with Big-3 arthritis blockbusters

      Ruby Khatun Khatun17 July 2017 9:50 AM IST
      ZURICH: Switzerland's Novartis is stocking up cheaper versions of the world's top-selling arthritis medicines, hoping a broad portfolio gives it an...
      GV Prasad launches Cancer Clinics in Hyderabad

      GV Prasad launches Cancer Clinics in Hyderabad

      Ruby Khatun Khatun17 July 2017 9:45 AM IST
      Hyderabad: 'Cancer Clinics', a start-up venture for dedicated cancer treatment, was launched here Saturday.It offers screening, information, advice on...
      Zydus Cadila gets USFDA nod for sclerosis drug

      Zydus Cadila gets USFDA nod for sclerosis drug

      Ruby Khatun Khatun17 July 2017 9:40 AM IST
      New Delhi: Drug firm Zydus Cadila said it has received tentative nod from the US health regulator to market Fingolimod capsules used for treatment of...
      Abbott, Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies

      Abbott, Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies

      Ruby Khatun Khatun17 July 2017 9:35 AM IST
      Abbott and Bigfoot Biomedical announced that the companies have entered into an agreement to develop and commercialize diabetes management systems,...
      CDSCO urges Pharma Companies for urgent release of stocks after Relabeling

      CDSCO urges Pharma Companies for urgent release of stocks after Relabeling

      Ruby Khatun Khatun17 July 2017 9:32 AM IST
      There has been a reported shortage of essential medicines after implementation of GST on 1st July 2017. Responding to the news, Central Drugs Standard...
      Nutraceuticals market may grow to 10 billion dollar by 2022: Assocham

      Nutraceuticals market may grow to 10 billion dollar by 2022: Assocham

      Ruby Khatun Khatun17 July 2017 9:07 AM IST
      Mumbai: Indian nutraceuticals market is expected to grow at a compounded annual growth rate of 21 per cent and reach USD 10 billion by 2022 from USD 4...
      CDSCO calls Stakeholder meeting for feedback on Sugam, check out details

      CDSCO calls Stakeholder meeting for feedback on Sugam, check out details

      Ruby Khatun Khatun16 July 2017 12:06 PM IST
      Through a recent notice CDSCO have invited stakeholders for meeting regarding the feedback on new modules of SUGAM portal which will be held at FDA...
      Stryker awarded 248.7 million dollar in patent case against Zimmer

      Stryker awarded 248.7 million dollar in patent case against Zimmer

      Ruby Khatun Khatun16 July 2017 10:03 AM IST
      A U.S. judge has increased the amount medical device maker Zimmer Biomet Holdings Inc must pay Stryker Corp for infringing patents on a surgical...
      Alembic Pharma opens Rs 300 crore anti-cancer drug unit in Gujarat

      Alembic Pharma opens Rs 300 crore anti-cancer drug unit in Gujarat

      Ruby Khatun Khatun16 July 2017 10:03 AM IST
      VADODARA: Drug firm Alembic Pharmaceuticals Ltd (APL) entered into oncology segment by inaugurating a Rs 300 crore anti-cancer drug facility at Halol...
      Amgen gets FDA approval for BLINCYTO (blinatumomab) to treat Acute Lymphoblastic Leukemia

      Amgen gets FDA approval for BLINCYTO (blinatumomab) to treat Acute Lymphoblastic Leukemia

      Ruby Khatun Khatun16 July 2017 9:40 AM IST
      THOUSAND OAKS, Calif.: Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
      FDA Advisory Committee Recommends Approval of Mylan and Biocon

      FDA Advisory Committee Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab

      Ruby Khatun Khatun16 July 2017 9:10 AM IST
      HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India: Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA)...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok